We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,465

Intellectual Property Weekly Abstracts Bulletin Week Of July 31, 2017
  • Borden Ladner Gervais LLP
  • Canada
  • August 2 2017

This is an appeal of the Federal Court’s decision allowing Gilead’s claim to invalidate Idenix’s ‘191 Patent on the grounds of insufficient disclosure


Intellectual Property Weekly Abstracts Bulletin Week of July 17, 2017
  • Borden Ladner Gervais LLP
  • Canada
  • July 19 2017

In this case, AbbVie brought an application against Samsung pursuant to the NOC Regulations. The parties agreed that a protective order was needed


Canada’s patent linkage regulations get long-awaited makeover
  • Osler Hoskin & Harcourt LLP
  • Canada
  • July 18 2017

On July 15, 2017, the Government of Canada proposed major amendments to the Patented Medicines (Notice of Compliance) Regulations (Regulations), the


Supreme Court of Canada Promises New Utility Test for Patents
  • Blake Cassels & Graydon LLP
  • Canada
  • July 18 2017

What does “useful”, one of the basic requirements for the patentability of an invention, mean in Canadian patent law? On June 30, 2017, in


Amendments to Canada’s patent linkage provisions relating to generic and biosimilar market approval
  • DLA Piper LLP
  • Canada
  • July 17 2017

On July 14, 2017, long-awaited amendments to Canada's patent linkage provisions (the Patented Medicines (Notice of Compliance) Regulations


Curtain lifted on proposed amended PM(NOC) Regulations
  • Gowling WLG
  • Canada
  • July 17 2017

The curtain has been lifted to reveal the proposed amendments to the Patented Medicines (Notice of Compliance) Regulations (the “Amended


Supreme Court of Canada Rules on the Promise of a Patent
  • Miller Thomson LLP
  • Canada
  • July 11 2017

On June 30, 2017, the Supreme Court of Canada issued its much awaited decision on the so-called “promise doctrine” of patent utility (AstraZeneca


FC Strikes PM(NOC) Application Due to No Chance of Success
  • PCK Perry + Currier Inc Currier + Kao LLP
  • Canada
  • July 5 2017

Applications brought under the Patented Medicines (Notice of Compliance) Regulations (“the PM(NOC) Regulations”) are likely to be dismissed if it is


Dow obtains largest Canadian patent infringement award in history
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • July 5 2017

The Federal Court has issued its Further Judgment and Reasons (2017 FC 637) concerning the amount of financial compensation to be paid to the Dow


Supreme Court Rejects the “Promise of the Patent”, Redefines Canada’s Patent Utility Requirement
  • Fasken Martineau DuMoulin LLP
  • Canada
  • July 4 2017

The nine judges of the Supreme Court ruled on Friday that the so-called “promise doctrine” was not part of Canadian patent law, and laid out a new